Acthar Gel (autoinjector) is a drug owned by Mallinckrodt Ard Inc. It is protected by 1 US drug patent filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 25, 2041. Details of Acthar Gel (autoinjector)'s patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11752199 | Methods of modulating pericytes |
Feb, 2041
(16 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Acthar Gel (autoinjector) is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Acthar Gel (autoinjector)'s family patents as well as insights into ongoing legal events on those patents.
Acthar Gel (autoinjector)'s Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Acthar Gel (autoinjector)'s generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 25, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Acthar Gel (autoinjector) Generic API suppliers:
Corticotropin is the generic name for the brand Acthar Gel (autoinjector). 1 company has already filed for the generic of Acthar Gel (autoinjector). Check out the entire list of companies who have already received approval for Acthar Gel (autoinjector)'s generic
Alternative Brands for Acthar Gel (autoinjector)
There are several other brand drugs in the same treatment category and using the same active ingredient (Corticotropin) as Acthar Gel (autoinjector). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Mallinckrodt Ard |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Corticotropin. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Ani Pharms |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Corticotropin, Acthar Gel (autoinjector)'s active ingredient. Check the complete list of approved generic manufacturers for Acthar Gel (autoinjector)
About Acthar Gel (autoinjector)
Acthar Gel (Autoinjector) is a drug owned by Mallinckrodt Ard Inc. Acthar Gel (Autoinjector) uses Corticotropin as an active ingredient. Acthar Gel (Autoinjector) was launched by Mallinckrodt Ard in 1982.
Approval Date:
Acthar Gel (autoinjector) was approved by FDA for market use on 01 January, 1982.
Active Ingredient:
Acthar Gel (autoinjector) uses Corticotropin as the active ingredient. Check out other Drugs and Companies using Corticotropin ingredient
Dosage:
Acthar Gel (autoinjector) is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 40 UNITS/0.5ML | INJECTABLE | Prescription | INJECTION |
| 80 UNITS/ML | INJECTABLE | Prescription | INJECTION |